Beta-cell replacement therapy is currently seen as a potential cure to diabetes. Pancreatic islets transplantation has been proposed as a possible therapy to successfully replace beta-cells. However, this strategy has several countersides:
The starting material is a highly innovative and versatile family of protein-based biopolymers. It will be combined with cutting-edge technologies to form a coating that will provide a physiologically ideal environment for the implanted cells so that they can survive and function in the body without being identified as hostile.
Once implanted, the final structure will be safe and biocompatible, semipermeable and strategically assembled to allow insulin diffusion from the inside, but also the access to blood supplies and nutrient flows to the transplanted cells.
Despite their efficiently immunoisolating their content, the coating will be able to promote complete integration and fusion of the capsule and the surrounding tissues generating a real continuity between the inner and the outer cells.
The challenge consists in designing a capsule that ensures the appropriate interaction between trasplanted pancreatic cells and the host tissues.
If the biomaterial is recognized by the immune system as foreign, acute and chronic inflammatory phenomena may occur and may give rise to a fibrotic process. The formation of a fibrotic capsule around the implanted pancreatic cells would drastically reduce the permeability of the implant surface and, consequently, thwart insulin release and cause death of implanted cells by hypoxia.
Semi-permeable nature and adequate selectivity. That means that the membrane must be permeable to the entry of oxygen, nutrients and glucose into the capsule and to the insulin output, but it must also be impermeable to immune cells, antibodies and, ideally, to potentially toxic cytokines and complement proteins.
The surrounding cells from the host tissues must be able to interact with the implant, adhere to it and integrate it as a part of its own. In the short term, the implant must evolve from a discrete entity to an integrated cell niche that keeps its singularity but is connected to the rest of the organism.
That is a specialized capsule-host tissue integration. The rapid vascularization of the implant and, as a consequence, the easy and rapid access of the implanted cells to the bloodstream improve the cell survival and accelerate the kinetics of exchange of nutrients, glucose and insulin between the implant and the bloodstream.
We are an international, multidisciplinary team of scientists from different fields ranging from synthetic biology to nanobiotechnology, molecular and cellular biology.
Our consortium gathers 12 Partners spread across 8 countries including Universities, SMEs and research institutes.
Our project is funded under the European Commission’s Framework Programme for Research, Innovation and Technology Horizon2020.
Since June 2015, we are cooperating with a cross-disciplinary strategy and a unique objective:
to develop a smarter strategy to cope with diabetes.
stay connected with us
Prof. José Carlos Rodríguez Cabello